

AperTO - Archivio Istituzionale Open Access dell'Università di Torino

**Punica granatum Leaf Ethanolic Extract and Ellagic Acid as Inhibitors of Zika Virus Infection.
[*Donalisio M, *Rubiolo P co-corresponding authors]**

This is the author's manuscript

Original Citation:

Availability:

This version is available <http://hdl.handle.net/2318/1766995> since 2025-05-20T10:37:44Z

Published version:

DOI:10.1055/a-1232-5705

Terms of use:

Open Access

Anyone can freely access the full text of works made available as "Open Access". Works made available under a Creative Commons license can be used according to the terms and conditions of said license. Use of all other works requires consent of the right holder (author or publisher) if not exempted from copyright protection by the applicable law.

(Article begins on next page)

1 ***Punica granatum* leaf ethanolic extract and ellagic acid as inhibitors of Zika virus infection.**

2

3 Stefano Acquadro^{1a} Andrea Civra^{2a}, Cecilia Cagliero¹, Arianna Marengo¹, Massimo Rittà², Rachele
4 Francese², Cinzia Sanna³, Cinzia Bertea⁴, Barbara Sgorbini¹, David Lembo², Manuela Donalisio^{2**},
5 Patrizia Rubiolo^{1*}

6

7

8 ¹ Department of Drug Science and Technology, University of Turin, Turin, Italy

9 ²Department of Clinical and Biological Sciences, University of Turin, Orbassano; Italy;

10 ³ Department of Environmental and Life Sciences University of Cagliari, Cagliari, Italy

11 ⁴ Department of Life Sciences and Systems Biology, University of Turin, Turin, Italy

12

13 * Corresponding author:

14 Prof. Patrizia Rubiolo, Department of Drug Science and Technology, University of Turin, Via Pietro
15 Giuria, 9, 10125, Turin, Italy.

16 E-mail: patrizia.rubiolo@unito.it

17 Phone: +39-011-6707173

18 Fax: +39-011-2367661

19 ** Co-corresponding author:

20 Prof. Manuela Donalisio, Department of Clinical and Biological Sciences, University of Turin,
21 Regione Gonzole 10, 10043 Orbassano (To), Italy.

22 E-mail: manuela.donalisio@unito.it

23 Phone: +39-011-6705427

24 Fax: +39-011-9038639

25

26 ^a These authors contributed equally to this work

27

28 **Abstract**

29 Zika virus (ZIKV), an arthropod-borne flavivirus, is an emerging healthcare threat worldwide. ZIKV
30 is responsible for severe neurological effects, such as paralytic Guillain-Barrè syndrome, in adults,
31 and also congenital malformations, especially microcephaly. No specific antiviral drugs and vaccines
32 are currently available, and treatments are palliative but medicinal plants show great potential as
33 natural sources of anti-ZIKV phytochemicals. This study deals with the investigation of the
34 composition, cytotoxicity and anti-ZIKV activity of *Punica granatum* leaf ethanolic extract, fractions
35 and phytoconstituents. *Punica granatum* leaves were collected from different areas in Italy and
36 Greece in different seasons. Crude extracts were analyzed and fractionated, and the pure compounds
37 were isolated. The phytochemical and biomolecular fingerprint of the pomegranate leaves was
38 determined. The antiviral activities of the leaf extract, fractions and compounds were investigated
39 against the MR766 and HPF2013 ZIKV strains *in vitro*. Both the extract and its fractions were found
40 to be active against ZIKV infection. Of the compounds isolated, ellagic acid showed particular anti-
41 ZIKV activities, with EC₅₀ values of 30.86 µM for MR766 and 46.23 µM for HPF2013. The
42 mechanism of action was investigated using specific antiviral assays and it was demonstrated that
43 ellagic acid was primarily active as it prevented ZIKV infection and was able to significantly reduce
44 ZIKV progeny production. Our data demonstrate the anti-ZIKV activity of pomegranate leaf extract
45 and ellagic acid for the first time. These findings identify ellagic acid as a possible anti-ZIKV
46 candidate compound that can be used for preventive and therapeutic interventions.

47

48 **Keywords**

49 Zika virus, *Punica granatum*, Lythraceae, leaf ethanolic extract, phytochemical and biomolecular
50 fingerprint, antiviral, ellagic acid

51

52 **Abbreviations**

53 Aut, autumn samples; BHK21, Baby hamster kidney cell; BLAST, basic local alignment search tool;
54 BSTFA, *N,O*-Bis(trimethylsilyl) trifluoroacetamide; CC₅₀, 50%-cytotoxic concentrations; C.I.,
55 Confidence intervals; DAPI, 4',6-diamidino-2-phenylindole; EC₉₀, effective concentration-90; ESI,
56 Electrospray ionization; FBS, foetal bovine serum; FDA, Food and Drug Administration; HBeAg,
57 Hepatitis B e Antigen; HBV, Hepatitis B; HIV-1, Human immunodeficiency virus type 1; HSV-2,
58 Herpes simplex virus type 2; HPV, Human Papilloma virus *I*_s, linear retention indices; *ITS*, Internal
59 transcribed spacer; MEM, Minimum Essential Medium; MOI, Multiplicity of infection; MTS, 3-(4,5-
60 Dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulphophenyl)-2H-tetrazolium, inner salt;

61 PC, Principal component; PDA, Photo diode array; PFU, Plaque-forming unit; PG, *Punica granatum*;
62 PGL8, *Punica granatum* leaf extract 8; Prep, preparative; *psbA-trnH*, chloroplast photosystem II
63 protein D1; RP, Reverse phase; RSD, Relative standard deviation; SPE, Solid phase extraction; SI,
64 Selectivity index; SIM, Selected Ion Monitoring; SRM, Selected Reaction Monitoring; Sum, summer
65 samples; VACV, Vaccinia virus; WHO, World Health Organization; ZIKV, Zikavirus
66

67 **Introduction**

68 Zika virus (ZIKV) is a mosquito-borne virus that belongs to the Flaviviridae family. It is primarily
69 transmitted by the bite of an infected mosquito from the *Aedes* genus, mainly *Aedes aegypti*, in
70 tropical and subtropical regions [1]. Outbreaks of ZIKV disease have been recorded in Africa, the
71 Americas, Asia and the Pacific and it is considered a global emerging healthcare threat. Since *Aedes*
72 *albopictus* has the capability to be a vector for ZIKV, other countries in temperate regions, such as
73 the Mediterranean basin, are potentially at risk [2]. ZIKV is usually responsible for asymptomatic or
74 mild self-limiting dengue-like diseases, which are characterized by fever, rash, conjunctivitis,
75 arthralgia and malaise. During the recent outbreak in Brazil, it has been associated with severe
76 neurological effects, such as Guillain-Barré syndrome and meningoencephalitis, in adults, and
77 congenital malformations, especially microcephaly, in infants born to infected mothers [3]. Despite
78 the severity of ZIKV complications, there are currently no FDA-approved vaccines. No specific
79 antiviral drugs are currently available and treatments are palliative and mainly directed towards the
80 relief of symptoms [1]. For these reasons, new effective preventive and therapeutic strategies against
81 ZIKV infection are urgently needed. Harnessing the potential of medicinal plants as natural sources
82 of anti-ZIKV phytochemicals, such as polyphenols and alkaloids [4], is a complementary and
83 alternative strategy. *Punica granatum* L. (Lythraceae family), commonly known as pomegranate, is
84 a domesticated tree that is widely grown as an evergreen in tropical regions, and as a deciduous tree
85 in temperate areas. It is an ancient plant that is well known in folk medicine and is becoming
86 increasingly popular as a functional food and nutraceutical source due to its high polyphenol content,
87 not only in the edible part, but also in other parts of the fruit and plant, including the peel, bark, leaves
88 and flowers [5]. Pomegranate is a rich source of a wide variety of compounds with beneficial
89 physiological activities, in particular antioxidative, anti-inflammatory and anti-cancerous properties
90 [6]. Nearly every part of the plant has been tested for antimicrobial activity, and roles in the
91 suppression of enteric infections, food preservation, wound healing, as well as gut and oral health
92 have been demonstrated [7]. Most antiviral studies have been performed on the fruit's peel and juice,
93 and it has been found that extracts exerted inhibitory activity against herpes simplex virus type 2
94 (HSV-2), human immunodeficiency virus type 1 (HIV-1) and the influenza virus [8-10]. Little
95 information has been reported on pomegranate leaf extracts, compared to other edible and non-edible
96 parts of the plant, although some recent studies have indicated that they may be an important source
97 of specialized bioactive metabolites and they possess a broad range of biological properties, such as
98 *in-vitro* antioxidant, anti-inflammatory, anti-cholinesterase and anti-proliferative activities [5,11,12].
99 This study explores the cytotoxicity and anti-ZIKV activity of pomegranate leaf ethanolic extracts,
100 as well as of the corresponding fractions and phytoconstituents after a phytochemical and

101 biomolecular characterization of the leaves, which were collected from various sites, after different
102 vegetative periods and in different years.

103 **Results and discussion**

104 Preliminary tests were carried out on a reference pomegranate leaf ethanolic extract (PGL8) to
105 investigate its anti-ZIKV activity in a specific virus plaque reduction assay against the African lineage
106 strain, 1947 Uganda MR766. A range of extract concentrations were added before and during the
107 infection, as well as after the removal of the virus inoculum. As reported in Figure 1S, Supporting
108 Information, the extract exerts remarkable antiviral activity, generating dose-response curves. Under
109 these conditions, the extract reduced the number of viral plaques with an EC₅₀ value of 11.4 µg/mL
110 (Table 1). To exclude the possibility that antiviral activity was due to cytotoxicity, cells were treated
111 with the serially diluted extract and added to the cell culture medium for 72 hours at 37°C, and the
112 cellular viability was then determined by MTS assay. The CC₅₀ values were above 100 µg/mL,
113 indicating that the antiviral activity observed was not due to cytotoxicity (Table 1, Figure 2S,
114 Supporting Information). Since the extract was resuspended in a DMSO/H₂O solution (50%/50%), a
115 control sample with equal volumes of DMSO/H₂O was included in all cell-culture experiments in
116 order to rule out the possibility of the solvent having a cytotoxic effect. The selectivity index (SI),
117 which measures the preferential antiviral activity of a drug in relation to its cytotoxicity, was 10.84.
118 Two unrelated DNA viruses, HSV-2 and VACV, were assessed in order evaluate the antiviral
119 specificity of PGL8. As reported in Table 1, the extract exerted relevant inhibitory activity against
120 HSV-2, with an SI of 47.08. These data confirmed the anti-HSV-2 effect that had been observed in
121 extracts derived from pomegranate fruit, including rind and juice [8]. By contrast, we did not observe
122 any inhibition of VACV infectivity.

123 The characterization of the pomegranate leaf ethanolic extract (sample PGL8) was carried out by
124 HPLC-PDA-MS/MS and GC-MS after derivatization with bis(trimethylsilyl)trifluoroacetamide to
125 obtain trimethylsilyl derivatives, and three different chemical classes of specialized metabolites were
126 revealed: phenolics, flavonoids and triterpenes. A list of the identified and putatively identified
127 compounds is reported in Table 2, while the HPLC-PDA and GC-MS profile are found in Figures 3S
128 and 4S, Supporting Information, respectively. In accordance with the current literature, flavones and
129 flavonols are the most representative specialized metabolites in the extract, and often exist as
130 glycosides of luteolin, apigenin and quercetin. Ellagic acid is the most abundant compound, while
131 hydrolyzable tannins, such as punicalins and punicalagins, which are markers of the other parts of the
132 pomegranate plant, were not detected. In addition, the presence of a pseudomolecular ion at *m/z* 455,
133 in negative mode, with a fragment at *m/z* 407 (M-HCHO-H₂O-H)⁻, and of a pseudomolecular ion at

134 *m/z* 457, in negative ionization mode, in the LC-MS profiles indicates the present of triterpenoid
135 molecules, but with evident coelution. A GC-MS analytical platform was therefore used and enabled
136 oleanolic, betulinic and ursolic acids to be identified after their derivatization in the extract.

137 To ensure consistent quality and reproducible activity in the pomegranate leaf extracts, genotypic and
138 phenotypic stability were evaluated by comparing the phytochemical and biomolecular patterns of
139 leaves that belonged to plants of different origins (see table 1S, Supporting Information), that were
140 harvested in different vegetative periods (summer and autumn) and in different years (2017 and
141 2018).

142 HPLC-PDA-MS/MS and GC-MS profiles were qualitatively consistent and all markers were detected
143 in all of the samples. Quantitation results, reported in Table 2S, Supporting Information, showed
144 differences in the abundances of some compounds in the leaf extracts. The repeatability results
145 showed that RSD% never exceeded 5%, while intermediate precision in the different extracts showed
146 RSD% of below 15%. The accuracy of the data was determined by comparing, when available, the
147 UV and MS quantification results, and the RSD% never exceeded 20%. Principal Component
148 Analysis was then applied to highlight similarities and differences between the samples. Figure 1
149 reports the score and loading plots of the first principal component (PC1) against the second principal
150 component (PC2), showing homogenous sample distribution in the score plot (no cluster of samples
151 are formed) and a good explained variance (39.14% for PC1 and 19.72% for PC2). No clear
152 discrimination between the samples was observed, although the autumn samples show slightly higher
153 contents of ellagic acid and its hexoside (both positively correlated with PC2, as can be seen in the
154 loading plot). In general, the few differences in the phenolics and triterpenes can be ascribed to
155 phenotypical variability and environmental factors.

156 To further confirm the quality and reproducibility of the pomegranate leaf extracts, a genotypic
157 fingerprint of the collected leaves was obtained using a DNA barcoding approach [13]. The nuclear
158 internal transcribed spacer region (*ITS*) and the chloroplast photosystem II protein D1 (*psbA-trnH*)
159 genes were amplified and sequenced for each site from which pomegranate leaf samples were
160 harvested. The sequences were deposited in the GenBank (Table 3S, Supporting Information) and
161 compared to those present in the database (fifty-nine *P. granatum ITS* sequences originating from
162 India, Iran and China and twenty-seven *P. granatum psbA-trnH* sequences from Iran, Tunisia, China
163 and Italy (Apulia, Latium, Sardinia, Padua and Trieste)).

164 Figures 5S and 6S, Supporting Information report no variation in the *ITS* and *psbA-trnH* nucleotide
165 composition for the eleven sites, suggesting that these biomolecular markers are stable. A consensus
166 sequence for each DNA region was obtained from the alignment of all the samples. A BLAST
167 alignment of the consensus, with all the data present in the database, showed a percentage of identity

168 among the *P. granatum* sequences that ranged from 100% to 96.89% for *ITS*, and from 100% to
169 97.64% for *psbA-trnH*, confirming intra-species stability and higher inter-species variability.
170 Interestingly, the comparison with *psbA-trnH* from Italian regions (accession numbers: HG765008,
171 HG765007, HG765006, HG765005), showed 100% similarity, supporting the stability of the species
172 in Italy.

173 Based on the data obtained from the phytochemical characterization, representative summer and
174 autumn pool extracts were created.

175 A bio-guided fractionation procedure was performed to attribute the antiviral activity to a specific
176 fraction and/or single components of the pomegranate leaf extracts. The summer and autumn extracts
177 were submitted to SPE fractionation, resulting in two fractions: a phenolic fraction (yield 73%) eluted
178 with methanol/water 85:15 (PGAut85, PGSum85), and a triterpenoid fraction (yield 5%) eluted with
179 methanol/water 95:05 (PGAut95, PGSum95). Table 2S, Supporting Information reports the quali-
180 quantitative composition of the four samples. The phenolic fraction was characterized by ellagic acid,
181 rutin, apigenin, quercetin and luteolin glycosides. In the PGAut85 fraction, ellagic acid was the most
182 abundant compound, while, in the PGSum85 one, luteolin 4'-*O*-glucoside was the main compound,
183 although a good amount of ellagic acid was detected. The triterpenoid fraction was characterized by
184 oleanolic, betulinic and ursolic acids.

185 As reported in Table 1 and Figure 7S, Supporting Information, both the PGAut85 and PGSum85
186 fractions were active against ZIKV at increasing doses with EC₅₀ values of 10.40 and 16.20 µg/mL,
187 respectively. However, no PG95 fractions exerted antiviral activity. No statistical differences were
188 observed in the EC₅₀ values of the summer and autumn fractions, confirming the demonstrated similar
189 chemical compositions of the pomegranate leaves. The main components of the PG85 and PG95
190 fractions were therefore tested. A preliminary screening was performed to test the activity of the
191 phenolic and triterpenic compounds at three doses (33, 11, 3.7 µg/mL) against the MR766 strain by
192 treating cells before, during and after infection. Table 3 demonstrates that ellagic acid was active
193 against ZIKV infection in a dose-dependent manner. No inhibitory effect was observed at any dose
194 for the other compounds. These data, obtained on cell cultures, did not confirm the predictive
195 inhibitory activity of luteolin, apigenin and rutin as inhibitors of the ZIKV NS2B-NS3 protease, as
196 identified by molecular docking [14,15]. Furthermore, the ability of quercetin 3-*O*-glucoside to inhibit
197 ZIKV *in vitro*, as reported in the literature, was not reproduced [16]. According to our data, ellagic
198 acid showed the highest antiviral activity against ZIKV, and was therefore isolated from the
199 pomegranate extract, by Prep-LC, and selected for further study. The isolated ellagic acid was
200 characterized by ¹H NMR and its spectrum compared with that of the commercial standard (Figure

201 8S, Supporting Information). The purity of the compound was determined by HPLC-PDA and
202 calculated to be >97%.

203 To confirm the inhibition of ZIKV infectivity that the isolated ellagic acid demonstrated in the
204 preliminary standard plaque reduction assay, a wider range of concentrations was tested against the
205 MR766 strain in order to determine the EC₅₀ values. High inhibitory activity was observed with an
206 EC₅₀ value of 30.86 μM (Table 4, Figure 2A). It is worth noting that the compound was also active
207 against the Asian lineage strain, 2013 French Polynesia HPF2013, with an EC₅₀ of 46.23 μM,
208 indicating the broad spectrum of its action against different ZIKV strains. These data were confirmed
209 using the commercially available standard, endowed with comparable EC₅₀ values (Table 4 and
210 Figure 2B). To corroborate the inhibition of ZIKV infectivity by ellagic acid, immunofluorescence
211 experiments that incubated fixed cells with a flavivirus group antigen antibody, were performed in
212 the same conditions as described previously for both MR766 and HPF2013. As reported in Figure 2C
213 and 2D, the analysis by confocal laser scanning microscope, revealed a strong red signal from ZIKV
214 protein E in the cytosol of untreated cells. A dose-dependent signal was observed in treated cells; the
215 highest tested dose (109.2 μM) completely inhibited the infectivity of both strains, while the number
216 of infected cells was considerably reduced at 36.4 μM.

217 Recently, the antiviral activity of ellagic acid, which had been isolated from other plants, has been
218 demonstrated *in vitro* against different RNA viruses, such as the influenza virus, Ebolavirus, Hepatitis
219 C virus, and HIV-1 [17-20]. Furthermore, ellagic acid has revealed potential activity against HBV
220 infection due to its hepatoprotective properties and ability to effectively block HBeAg secretion in
221 cells [21]. By contrast, ellagic acid partially inhibited HSV-2 infection [8]. Herein, we have
222 demonstrated, for the first time, the antiviral activity of pomegranate-derived ellagic acid against
223 ZIKV, a member of the Flaviviridae family. Previously, other polyphenols, such as delphinidin and
224 epigallocatechin gallate, have been shown to have anti-flaviviral effects [22]. Our data have
225 demonstrated that the isolated ellagic acid inhibited, *in vitro*, the infection of two lineages, the African
226 one, which is responsible for more acute infection, and Asian ZIKV, which is associated with
227 neurological impairments [23]. Interestingly, the compound also exerted adulticidal activity against
228 *Aedes aegypti* mosquito, the main vector of the virus [24].

229 As ellagic acid was identified as an inhibitor compound of ZIKV infectivity, further studies were
230 performed to elucidate its mechanism of action. Firstly, we tested the ability of isolated ellagic acid
231 to reduce ZIKV progeny production *in vitro* by performing a virus yield reduction assay. The
232 experimental procedure for this assay is similar to the one described for the viral plaque reduction
233 assay, but the viral titers of the samples were evaluated after infection. As reported in Figure 3, 109.2

234 and 36.4 μM concentrations significantly reduced the production of infectious viruses 100- and 10-
235 fold, respectively.

236 A virucidal assay was performed to investigate the possible direct virus-inactivating activity of the
237 isolated compound on both MR766 and HPF2013. To this aim, 10^5 pfu of the ZIKV strains and the
238 compound, at the dose corresponding to the EC_{90} values, were mixed and incubated for 2 hours at
239 either 4 or 37°C . As reported in Figure 9S, Supporting Information, no inhibition by the isolated
240 ellagic acid was observed under any experimental conditions either for MR766 or HPF2013, thus
241 excluding the possibility that the direct inactivation of extracellular virus particles may be a mode of
242 antiviral action. The time-of-addition assay allowed us to investigate the stage of the virus replication
243 cycle at which the compound acts by targeting the cellular surface or intracellular processes. To this
244 aim, the compound was added to the cells at different times of infection only before, during, or after
245 infection. In all of the experiments, DMSO-treated infected cells were used as controls, and plaque-
246 formation inhibition was evaluated. Figure 3C shows that the isolated compound exerted inhibitory
247 activity against the MR766 strain in a dose-response manner, when added 2 hours before infection,
248 with an EC_{50} value of 74.48 μM . By contrast, inhibition was absent in the during-treatment assay,
249 whereas weak inhibition was observed at the higher doses tested in the post-treatment assay. These
250 data were confirmed using the HPF2013 (panel D) strain with inhibitory activity being observed in
251 the pre-treatment assay with a value of 93.01 μM . The ability to inhibit viral infection during the pre-
252 treatment assay was also observed when cells were treated with the commercial compound (data not
253 shown). These data suggest that ellagic acid primarily reduces cell susceptibility to virus infection by
254 tethering to the cell surface.

255 Our results demonstrate that ellagic acid did not affect the ZIKV infection by directly inactivating the
256 virus particles. The time-of-addition experiments indicated that ellagic acid, added before viral
257 exposure, suppressed viral replication, which suggests that, mechanistically, the compound interferes
258 with the cell surface, likely masking ZIKV receptors, including Ax19, on target cells, prior to viral/cell
259 membrane fusion. Similar ellagic-acid activity was observed against HIV-1. However, in this case, it
260 was also shown to be able to specifically block viral integrase activity [18]. Furthermore, ellagic acid
261 has been observed to have a HPV-preventive effect in clinical trials; women treated with the ellagic
262 acid complex were less likely to be diagnosed with an abnormal Pap smear at 6 months [25].

263 The absence of activity when the compound was added, with the virus, to the cells indicates that it
264 did not impair the early intracellular steps of viral replication or viral targets. This hypothesis was
265 confirmed by performing a binding assay, and it was shown that a high concentration of isolated
266 compound did not inhibit the binding of either MR766 or HPF2013 to the host-cell surface (Figure
267 10S, Supporting Information).

268 Further studies are required to clarify whether the anti-ZIKV activity of ellagic acid may also occur
269 indirectly via an alteration in the innate response of the infected target cells. In recent years, ellagic
270 acid has gained attention due to its antioxidant, anticancer, antiallergic and anti-inflammatory
271 activities. Its antioxidant properties have been associated with hepatoprotective activity, the
272 attenuation of liver injury during Hepatitis B infection and with therapeutic effects on the survival of
273 influenza-challenged mice, in combination with an antiviral drug and an immunomodulator [26,27].
274 Our current data suggest that ellagic acid may be a promising candidate for the development of a
275 novel anti-ZIKV compound. Further structural modifications might be needed to improve its
276 selectivity index.

277 In summary, we have demonstrated, for the first time, that pomegranate leaf extract and its fractions
278 possess anti-ZIKV activity. The lack of a protective vaccine and specific treatment against ZIKV has
279 prompted us to develop safe and effective anti-ZIKV compounds that are also able to prevent
280 infection by impairing the chain of congenial transmission. The pomegranate leaf ethanolic extract
281 is characterized by hydrolyzable tannins, flavonoids and triterpenes, its phytochemical pattern is
282 stable and does not depend on geographical conditions or season. Furthermore, no differences were
283 found in the *ITS* and *psbA-trnH* sequences extracted from leaves collected in different sites.
284 Moreover, leaf collection is sustainable as it does not cause damage to the plant during spring pruning
285 or in the fall. Ellagic acid was identified, from among the isolated constituents, as an interesting
286 antiviral compound for its inhibitory activity, ability to prevent infection and reduce the transmission
287 of extracellular free virus at high titers. Further work must still be done to elucidate the cellular targets
288 involved in this antiviral action and to assess ellagic acid's clinical potential as a preventive and/or
289 therapeutic compound.

290 **Materials and methods**

291 *Plant materials*

292 *Punica granatum* leaves were collected from different sites in Sardinia, and occasionally other Italian
293 regions, and in Greece from June to October 2017 and 2018 (Table 1S, Supporting Information).
294 Sample 8 was from the botanical garden of the University of Cagliari, Italy. All individuals sampled
295 from other sites were collected randomly. Voucher specimens (Table 1S) were deposited at the
296 Cagliari's botanical garden and at the Department of Drug Science and Technology of the University
297 of Torino. The fresh plant materials were dried at 40°C to constant weight.

298 *Chemicals*

299 LC-MS grade acetonitrile, HPLC-grade methanol, pyridine, *N,O*-Bis(trimethylsilyl)
300 trifluoroacetamide (BSTFA), formic acid (>98% purity), ellagic acid, rutin and apigenin were
301 purchased from Merck. De-ionized water (18.2 MΩ cm) was obtained from a Milli-Q purification
302 system (Millipore)). Luteolin, apigenin 7-*O*-glucoside, quercetin 3-*O*-glucoside, luteolin 7-*O*-
303 glucoside, luteolin 4'-*O*-glucoside, betulinic acid, oleanolic acid and ursolic acid were obtained from
304 Extrasynthese.

305 *Ethanol extract preparation*

306 Two extracts were prepared from each sample. 0.500 g of dried and ground powder was extracted
307 using an ultrasonic bath (Soltec, Sonica S3 EP 2400) operating at 40 KHz with 10 mL of ethanol,
308 three times for 10 min each. The supernatants were combined and centrifuged at 5000 rpm for 10
309 min, poured into a glass balloon and evaporated in a rotary evaporator under vacuum at a temperature
310 below 50°C. In order to reduce chlorophyll interference, 30 mg of crude extract were resuspended in
311 1 mL of methanol/water (20:80, v/v), loaded onto a Bond Elut Jr 500mg SPE-C18 cartridge (Agilent
312 Technologies), eluted with 8 mL of methanol/water (95:5, v/v) and evaporated in a rotary evaporator.
313 Pool samples, obtained by mixing the leaves that were harvested in summer (PGSum) and autumn
314 (PGAut), were also created and extracted in the same way.

315 *HPLC-PDA-MS/MS analysis*

316 For each extract, a 10 mg/mL stock solution in methanol was prepared, subsequently diluted with
317 acetonitrile/water (95:5, v/v) and filtered through a 13 mm diameter, 0.22 μm PTFE syringe
318 hydrophilic filter before HPLC-PDA-MS/MS analyses. Each extract (5 μL) was analyzed using a
319 Shimadzu Nexera X2 system equipped with a photodiode array detector SPD-M20A that was
320 connected, in series, to a Shimadzu LCMS-8040 triple quadrupole system outfitted with an
321 electrospray ionization (ESI) source (Shimadzu). The chromatographic conditions were: column:
322 Ascentis Express RP-Amide (10 cm × 2.1 mm, 2.7 μm, Supelco); mobile phases: A water/formic acid
323 (999:1, v/v) and B acetonitrile/formic acid (999:1, v/v); flow rate: 0.4 mL/min; column temperature:
324 30 °C; gradient: 5% B for 5 min, 5–25% B in 35 min, 25–100% B in 10 min, 100% B for 1 min. UV
325 spectra were acquired over the 220–450 nm wavelength range. The mass spectrometer operation
326 conditions and identification criteria were as reported by Marengo *et al.* (2017) [33]. Quantitation
327 was performed using the external standard calibration method via UV (at the λ max for each
328 compound) and Selected Reaction Monitoring (SRM) acquisition in ESI⁺ (collision energy: 35.0 V
329 for ESI⁺, dwell time: 20). The results are expressed as mg of compound per g of dried leaves (mg/g).
330 When the commercial standard was not available, quantification was based on the UV calibration
331 curves of compounds belonging to the same chemical class. The calibration ranges, λ max, SRM

332 transitions and analytical performance of the method are reported in Table 5S. Analyses were
333 performed in triplicate. All data were processed using LabSolution software (Shimadzu).

334 *GC-MS analysis*

335 GC analysis were carried out on a Shimadzu 2010 GC unit that was coupled to a Shimadzu QP2010
336 Mass spectrometer and that made use of a MPS-2 multipurpose sampler (Gerstel). The derivatization
337 of the extracts was performed with bis(trimethylsilyl)trifluoroacetamide to obtain trimethylsilyl
338 derivatives, as reported by Rubiolo *et al.* 2013 [34]. GC-MS analyses were carried out on a MEGA-
339 1 column (100% methylpolysiloxane, 15 m × 0.18 mm d_c , 0.18 μm d_f) from MEGA S.r.l. (Milan,
340 Italy). Analytical conditions: injector temperature: 300°C, transfer line temperature: 320°C, carrier
341 gas: He (0.8 ml/min), split ratio 1:10. Temperature program: 50°C(2min)//5°C/min//300°C. MS
342 conditions: source temperature: 200°C, ionization mode: electron impact (70 eV), scan rate: 0.2 u/s,
343 mass range: 100–650 m/z . Compounds were identified via comparisons of mass spectra and linear
344 retention indices (I_s), calculated versus a C9-C25 hydrocarbon mixture, with those reported in the
345 literature. The identity of the triterpenoids was confirmed by the co-injection of commercially
346 available standards. The quantitation of the triterpenoids was performed in SIM-acquisition mode
347 using the external standard calibration method, according to Rubiolo *et al.* 2013 [34] (Table 6S). Data
348 were processed using Shimadzu GCMS Solution software (Shimadzu)

349 *DNA extraction, PCR amplification and sequencing*

350 The DNA extraction, PCR amplification and sequencing of the *ITS* and *psbA-trnH* regions were
351 performed according to Marengo *et al.* (2019) [13] without modifications. Table 4S, Supporting
352 Information reports the list of primers used in PCR and sequencing.

353 *SPE-C18 cartridge and preparative LC (Prep-LC) fractionation*

354 Crude PGSum and PGAut ethanolic extracts were fractionated using a SPE-C18 cartridge: 30 mg of
355 each crude extract were resuspended in 1 mL of methanol/water (20:80, v/v), loaded onto the Bond
356 Elut Jr 500mg SPE-C18 cartridge, first eluted with 5 mL of methanol/water 85:15, v/v (PG85) and
357 subsequently with 5 mL of methanol/water 95:05, v/v (PG95). Both fractions were evaporated to
358 dryness. Fraction PGAut85, at a concentration of 40 mg/mL, was injected into a Shimadzu LC-10AT
359 system to isolate the ellagic acid. Chromatographic conditions: column: Ascentis Express RP-Amide
360 (15cm × 10mm, 5 μm , Supelco) mobile phases: see HPLC-PDA-MS/MS analysis; flow rate: 1
361 mL/min; column temperature: 30°C; gradient program: 10% B for 1 min, 10–30% B in 60 min, 30–
362 51% B in 9 min, 51–100% B in 1 min, 100% B for 4 min; injection volume: 100 μL . Ellagic acid was
363 collected via multiple injections, the organic solvent was evaporated with a rotary evaporator and the

364 sample was subsequently freeze-dried. The purity of the isolated ellagic acid was confirmed via a
365 HPLC-PDA-MS/MS analysis at a concentration of 1mg/ml in methanol, and was calculated as a
366 percentage peak area at 254 nm. Isolated and commercial ellagic acid were also characterized by ¹H
367 NMR. Spectra were collected in deuterated DMSO using a JEOL ECZR600 (600 MHz) nuclear
368 magnetic resonance (NMR) spectrometer.

369 *Cell cultures*

370 African green monkey fibroblastoid kidney cells (Vero cells, ATCC CCL-81) were grown as
371 monolayers in Eagle's Minimum Essential Medium (MEM) (Sigma-Aldrich) with 10% heat-
372 inactivated fetal bovine serum (FBS) (Sigma-Aldrich) and 1% antibiotic solution (Penicillin-
373 Streptomycin, Sigma-Aldrich) in a humidified 5% CO₂ atmosphere at 37° C. The antiviral assays,
374 against ZIKV and HSV-2, were performed on Vero cells. BHK-21 cells (ATCC CCL-10) were grown
375 in DMEM 10% FBS, and used for antiviral assays against the Vaccinia virus (VACV). The embryonic
376 human kidney cells (293T) (ATCC CRL-3216) were grown as monolayer in DMEM 10% FBS
377 supplemented with 1% Glutamax-I (Invitrogen).

378 *Viruses*

379 Two ZIKV strains were used to investigate the antiviral potential of pomegranate: the 1947 Uganda
380 MR766, and the 2013 French Polynesia HPF2013, representing the African and the Asian lineages
381 respectively. The viruses were produced via the transfection of 293T cells with two plasmids
382 (pCDNA6.2 Zika MR766 Intron3115 HDVr MEG 070916 5 and pCDNA6.2 Zika HPF2013
383 3864,9388Intron HDVr MEG091316 2) kindly provided by Prof. F. Di Cunto and Prof. M. J. Evans,
384 and were propagated and titred in Vero cells, as described in Francese *et al.*, 2019 [23]. The HSV-2
385 strain (ATCC VR-540) was propagated, collected and titrated, via plaque assay, on Vero cells [28].
386 The Vaccinia virus (VACV, ATCC VR-1354) strain was propagated, collected and titrated, via plaque
387 assay, on BHK-21 cells.

388 *Viability assay*

389 Cell viability was assessed using the MTS assay, as described in Donalisio *et al.*, 2016 [29]. PGL8,
390 PGAUT85 and PGEST85 were re-suspended in a DMSO/H₂O solution (50%/50%), at 10 mg/mL
391 concentration; PGAUT95 and PGEST95 were re-suspended in a DMSO/H₂O solution (87.5%/12.5%)
392 at 2.5 mg/mL concentration; ellagic acid was re-suspended in DMSO at 10 mg/mL concentration.
393 The effects of the extract, fractions and ellagic acid on Vero-cell viability were evaluated at 24 and
394 72 hours. 50%-cytotoxic concentrations (CC₅₀) and 95% confidence intervals (C.I.) were determined
395 using Prism 5 software (Graph-Pad Software).

396 *Inhibition assays*

397 The anti-ZIKV activity of the extract, fractions and ellagic acid was determined using a viral plaque
398 reduction assay on Vero cells as described in Francese *et al.*, 2019 [23]. For the HSV-2 and VACV
399 plaque reduction assays, the cells were infected with virus at MOI 0.001 and 0.006 PFU/cell,
400 respectively, the cells were fixed and the plaques were counted at 24 (HSV-2) and 72 hours (VACV)
401 post infection. PGL8, PGAUT85 and PGEST85 were re-suspended in a DMSO/H₂O solution
402 (50%/50%) at 10 mg/mL concentration; PGAUT95 and PGEST95 were re-suspended in a
403 DMSO/H₂O solution (87.5%/12.5%) at 2.5 mg/mL concentration. Betulinic acid, oleanolic acid,
404 ursolic acid and apigenin were re-suspended in a DMSO/H₂O solution (70%/30%) at 7 mg/mL
405 concentration; apigenin 7-O-glucoside, luteolin, luteolin 4-O-glucoside, luteolin 7-O-glucoside,
406 quercetin 3-O-glucoside, rutin and ellagic acid were re-suspended in DMSO at 10 mg/mL
407 concentration. The concentrations that reduced viral infectivity by 50% (half maximal effective
408 concentration, EC₅₀) and concentrations that reduced viral infectivity by 90% (effective
409 concentration-90, EC₉₀) were calculated using the software Prism. The results are reported for three
410 independent experiments. The selectivity index (SI) was calculated as the ratio CC₅₀ / EC₅₀.

411 *Virus inactivation assay*

412 Ellagic acid preparations were investigated for their ability to directly inactivate ZIKV particles at
413 4°C and 37 °C [23]. Ellagic acid was re-suspended in DMSO at 10 mg/mL concentration.

414 *Time-of-addition assays*

415 Serial dilutions of ellagic acid were either added to Vero cells before infection for 2 hours at 37 °C,
416 during infection with MR766 (MOI 0.005), or after the infection [28]. Ellagic acid was re-suspended
417 in DMSO at 10 mg/mL concentration.

418 *Immunofluorescence assay*

419 Vero cells that were seeded on coverslips were treated with serial doses of plant-isolated ellagic acid
420 for 2 hours prior to infection, for two hours during infection with MR766 (MOI 1) and for 30 hours
421 after the absorption process, at 37 °C. The experiment was performed as described in Francese *et al.*,
422 (2019) [23], with the exception of the nucleic staining, which was performed using 4',6-diamidino-2-
423 phenylindole (DAPI, Sigma-Aldrich) 0.5 µg/mL for 10 minutes at room temperature. Ellagic acid
424 was re-suspended in DMSO at 10 mg/mL concentration.

425 *Virus yield reduction assay*

426 The experiment was conducted as described in Francese *et al.* (2019) [23]. Ellagic acid was re-
427 suspended in DMSO at 10 mg/mL concentration.

428 *Binding assay*

429 The experiment was conducted as described in Francese *et al.* (2019) [23]. Ellagic acid was re-
430 suspended in DMSO at 10 mg/mL concentration.

431 *Statistical analysis*

432 Antiviral data were analyzed using the Student's t-test and F-test on GraphPad Prism version 5.00
433 software, as appropriate. The Student's t-test was used to compare viral titers in virus inactivation
434 assays. Significance was reported for p-value <0.05. Principal Component Analysis was carried out
435 using Statistica 10 (StatSoft. Inc.) software. Sequence quality and alignment were performed as
436 reported by Marengo *et al.* (2019) [13].

437 **Supporting Information**

438 HPLC-PDA-MS/MS analysis conditions, GC-MS analysis conditions, SPE-C18 cartridge and
439 preparative LC (Prep-LC) fractionation conditions, Anti-ZIKV activity of a reference pomegranate
440 leaf ethanolic extract PGL8 (Fig. 1S), Cell viability assays (Fig. 2S), LC chromatograms of the
441 pomegranate leaf extract PGL8 (Fig. 3S), GC-MS chromatograms of the pomegranate leaf extract
442 PGL8 (Fig. 4S), Comparison of *ITS* sequences between the eleven *Punica granatum* samples (Fig.
443 5S), Comparison of *psbA-trnH* sequences between the eleven *Punica granatum* samples (Fig. 6S),
444 Anti- MR766 activity of PGSum85, PGSum95, PGAut85 and PGAut95 (Fig. 7S), ¹H 600 MHz NMR
445 of ellagic acid isolated with LC-Prep and of the commercial standard reference (Fig. 8S), Inactivation
446 of MR766 particles by isolated ellagic acid (Fig. 9S), Effect of isolated ellagic acid on virus binding
447 to cells (Fig. 10S), Location, coordinates, and code of pomegranate leaf samples (Table 1S),
448 Concentration of phenolic compounds and triterpenes in the different pomegranate leaf extracts and
449 in the fractions (Table 2S), List of the sequences obtained from *P. granatum* samples deposited in
450 GenBank (table 3S), List of primers used in PCR and sequencing (Table 4S), Quantification method,
451 linearity range, R² and calibration curve of the main compounds by UV and SRM methods (Table
452 5S) and Target ion, qualifier ions, linearity range, R² and calibration curve of triterpenoids quantified
453 by GC-MS (Table 6S) are available as Supporting Information.

454 **Acknowledgments**

455 This work was supported by the Ricerca Locale (ex-60% 2018) grant from the University of Turin, Turin, Italy

456 **Conflict of interest**

457 The authors declare no conflict of interest.

458

459 **References**

- 460 1. Saiz JC, Vazquez-Calvo A, Blazquez AB, Merino-Ramos T, Escribano-Romero E, Martin-
461 Acebes MA. Zika Virus: the Latest Newcomer. *Front Microbiol* 2016; 7: 496
- 462 2. WHO. Zika virus [WWW Document], n.d. URL [https://www.who.int/news-room/fact-](https://www.who.int/news-room/fact-sheets/detail/zika-virus)
463 [sheets/detail/zika-virus](https://www.who.int/news-room/fact-sheets/detail/zika-virus) (accessed 05.04.20). DOI:
- 464 3. Blázquez A-B, Saiz J-C. Neurological manifestations of Zika virus infection. *World J Virol*
465 2016; 5: 135-143
- 466 4. Batista MN, Braga ACS, Campos GRF, Souza MM, Matos RPA, Lopes TZ, Candido NM,
467 Lima MLD, Machado FC, Andrade STQ, Bittar C, Nogueira ML, Carneiro BM, Mariutti RB,
468 Arni RK, Calmon MF, Rahal P. Natural Products Isolated from Oriental Medicinal Herbs
469 Inactivate Zika Virus. *Viruses* 2019; 11:
- 470 5. Fellah B, Bannour M, Rocchetti G, Lucini L, Ferchichi A. Phenolic profiling and antioxidant
471 capacity in flowers, leaves and peels of Tunisian cultivars of *Punica granatum* L. *J Food Sci*
472 *Technol* 2018; 55: 3606-3615
- 473 6. Vucic V, Grabez M, Trchounian A, Arsic A. Composition and Potential Health Benefits of
474 Pomegranate: A Review. *Curr Pharm Des* 2019; 25: 1817-1827
- 475 7. Howell AB, D'Souza DH. The Pomegranate: Effects on Bacteria and Viruses That Influence
476 Human Health. *Evid Based Complement Alternat Med* 2013; 2013: 606212
- 477 8. Arunkumar J, Rajarajan S. Study on antiviral activities, drug-likeness and molecular docking
478 of bioactive compounds of *Punica granatum* L. to Herpes simplex virus - 2 (HSV-2). *Microb*
479 *Pathog* 2018; 118: 301-309
- 480 9. Haidari M, Ali M, Ward Casscells S, Madjid M. Pomegranate (*Punica granatum*) purified
481 polyphenol extract inhibits influenza virus and has a synergistic effect with oseltamivir.
482 *Phytomedicine* 2009; 16: 1127-1136
- 483 10. Neurath AR, Strick N, Li Y-Y, Debnath AK. *Punica granatum* (Pomegranate) juice provides
484 an HIV-1 entry inhibitor and candidate topical microbicide. *BMC Infect Dis* 2004; 4: 41-41
- 485 11. Bekir J, Mars M, Souchard JP, Bouajila J. Assessment of antioxidant, anti-inflammatory, anti-
486 cholinesterase and cytotoxic activities of pomegranate (*Punica granatum*) leaves. *Food Chem*
487 *Toxicol* 2013; 55: 470-475
- 488 12. Boggula N, Peddapalli H. Phytochemical Analysis and Evaluation of In Vitro Anti Oxidant
489 Activity of Punica Granatum Leaves. *Int J Pharmacogn Phytochem Res* 2017; 9: 1110-1118
- 490 13. Marengo A, Maxia A, Sanna C, Mandrone M, Berteà CM, Bicchi C, Sgorbini B, Cagliero C,
491 Rubiolo P. Intra-specific variation in the little-known Mediterranean plant *Ptilostemon*

- 492 *casabonae* (L.) Greuter analysed through phytochemical and biomolecular markers.
493 Phytochemistry 2019; 161: 21-27
- 494 14. Roy A, Lim L, Srivastava S, Lu Y, Song J. Solution conformations of Zika NS2B-NS3pro
495 and its inhibition by natural products from edible plants. PLOS ONE 2017; 12: e0180632
- 496 15. Yadav R, Selvaraj C, Aarthy M, Kumar P, Kumar A, Singh SK, Giri R. Investigating into the
497 molecular interactions of flavonoids targeting NS2B-NS3 protease from ZIKA virus through
498 in-silico approaches. J Biomol Struct Dyn 2020, DOI: 10.1080/07391102.2019.1709546: 1-
499 13
- 500 16. Wong G, He S, Siragam V, Bi Y, Mbikay M, Chretien M, Qiu X. Antiviral activity of
501 quercetin-3-beta-O-D-glucoside against Zika virus infection. Virol Sin 2017; 32: 545-547
- 502 17. Cui Q, Du R, Anantpadma M, Schafer A, Hou L, Tian J, Davey RA, Cheng H, Rong L.
503 Identification of Ellagic Acid from Plant *Rhodiola rosea* L. as an Anti-Ebola Virus Entry
504 Inhibitor. Viruses 2018; 10:
- 505 18. Promsong A, Chuenchitra T, Saipin K, Tewtrakul S, Panichayupakaranant P, Satthakarn S,
506 Nittayananta W. Ellagic acid inhibits HIV-1 infection in vitro: Potential role as a novel
507 microbicide. Oral Diseases 2018; 24: 249-252
- 508 19. Reddy BU, Mullick R, Kumar A, Sudha G, Srinivasan N, Das S. Small molecule inhibitors of
509 HCV replication from pomegranate. Sci Rep 2014; 4: 5411
- 510 20. Tran TT, Kim M, Jang Y, Lee HW, Nguyen HT, Nguyen TN, Park HW, Le Dang Q, Kim JC.
511 Characterization and mechanisms of anti-influenza virus metabolites isolated from the
512 Vietnamese medicinal plant *Polygonum chinense*. BMC Complement Altern Med 2017; 17:
513 162
- 514 21. Shin MS, Kang EH, Lee YI. A flavonoid from medicinal plants blocks hepatitis B virus-e
515 antigen secretion in HBV-infected hepatocytes. Antiviral Res 2005; 67: 163-168
- 516 22. Lee JL, Loe MWC, Lee RCH, Chu JJH. Antiviral activity of pinocembrin against Zika virus
517 replication. Antiviral Res 2019; 167: 13-24
- 518 23. Francese R, Civra A, Ritta M, Donalisio M, Argenziano M, Cavalli R, Mougharbel AS, Kortz
519 U, Lembo D. Anti-zika virus activity of polyoxometalates. Antiviral Res 2019; 163: 29-33
- 520 24. Ajaegbu EE, Danga SP, Chijoke IU, Okoye FB. Mosquito adulticidal activity of the leaf
521 extracts of *Spondias mombin* L. against *Aedes aegypti* L. and isolation of active principles. J
522 Vector Borne Dis 2016; 53: 17-22
- 523 25. Morosetti G, Criscuolo AA, Santi F, Perno CF, Piccione E, Ciotti M. Ellagic acid and *Annona*
524 *muricata* in the chemoprevention of HPV-related pre-neoplastic lesions of the cervix. Oncol
525 Lett 2017; 13: 1880-1884

- 526 26. Garcia-Nino WR, Zazueta C. Ellagic acid: Pharmacological activities and molecular
527 mechanisms involved in liver protection. *Pharmacol Res* 2015; 97: 84-103
- 528 27. Pavlova EL, Simeonova LS, Gegova GA. Combined efficacy of oseltamivir, isoprinosine and
529 ellagic acid in influenza A(H3N2)-infected mice. *Biomed Pharmacother* 2018; 98: 29-35
- 530 28. Ghosh M, Civra A, Ritta M, Cagno V, Mavuduru SG, Awasthi P, Lembo D, Donalisio M.
531 *Ficus religiosa* L. bark extracts inhibit infection by herpes simplex virus type 2 in vitro. *Arch*
532 *Virol* 2016; 161: 3509-3514
- 533 29. Donalisio M, Quaranta P, Chiuppesi F, Pistello M, Cagno V, Cavalli R, Volante M, Bugatti
534 A, Rusnati M, Ranucci E, Ferruti P, Lembo D. The AGMA1 poly(amidoamine) inhibits the
535 infectivity of herpes simplex virus in cell lines, in human cervicovaginal histocultures, and in
536 vaginally infected mice. *Biomaterials* 2016; 85: 40-53
- 537 30. Abdulla R, Mansur S, Lai H, Ubul A, Sun G, Huang G, Aisa HA. Qualitative Analysis of
538 Polyphenols in Macroporous Resin Pretreated Pomegranate Husk Extract by HPLC-QTOF-
539 MS. *Phytochem Anal* 2017; 28: 465-473
- 540 31. Wu S, Tian L. Diverse Phytochemicals and Bioactivities in the Ancient Fruit and Modern
541 Functional Food Pomegranate (*Punica granatum*). *Molecules* 2017; 22:
- 542 32. Sumner LW, Amberg A, Barrett D, Beale MH, Beger R, Daykin CA, Fan TWM, Fiehn O,
543 Goodacre R, Griffin JL, Hankemeier T, Hardy N, Harnly J, Higashi R, Kopka J, Lane AN,
544 Lindon JC, Marriott P, Nicholls AW, Reily MD, Thaden JJ, Viant MR. Proposed minimum
545 reporting standards for chemical analysis Chemical Analysis Working Group (CAWG)
546 Metabolomics Standards Initiative (MSI). *Metabolomics* : Official journal of the
547 Metabolomic Society 2007; 3: 211-221
- 548 33. Marengo A, Maxia A, Sanna C, Berteza CM, Bicchi C, Ballero M, Cagliari C, Rubiolo P.
549 Characterization of four wild edible *Carduus* species from the Mediterranean region via
550 phytochemical and biomolecular analyses. *Food Res Int* 2017; 100: 822-83
- 551 34. Rubiolo P, Casetta C, Cagliari C, Brevard H, Sgorbini B, Bicchi C. *Populus nigra* L. bud
552 absolute: a case study for a strategy of analysis of natural complex substances. *Anal Bioanal*
553 *Chem* 2013; 405: 1223-1235

554

555 **Figure legend**

556 **Figure 1.** Score plot (A) and loading plot (B) of the principal component analysis relative to the
557 quantity of the main markers of the pomegranate's leaf extracts.

558 **Figure 2.** Panels A and B. Plaque reduction assays infecting cells with MR766 (panel A) and
559 HPF2013 (panel B) in the presence of isolated and commercial ellagic acid. Vero cells were treated
560 with ellagic acid prior to infection, during the infection period, and after the infection for 72 hours.
561 Results are reported as percentage of infection in comparison to untreated controls (Y-axis); the
562 concentrations tested are reported on X-axis. Error bars represent the standard error of the mean for
563 three independent experiments. Panel C and D. Representative MR766 foci (panel C) and HPF2013
564 foci (panel D) in Vero cells by immunofluorescence assay. Vero cells were treated with ellagic acid
565 before, during, and after the infection. The ZIKV protein E is visualized in red, nuclei in blue. NI, not
566 infected; UT, untreated. Scale bar, 20 μ m. Ellagic acid was resuspended in a DMSO solution.

567 **Figure 3.** Panel A and B. Virus yield reduction assays. Effects of isolated ellagic acid on multiple
568 cycles of MR766 (panel A) and HPF2013 (panel B) replication. Viral titres are expressed as PFU/mL.
569 Error bars represent the standard error of the mean for three independent experiments ($p < 0.05$). Panel
570 C and D. Time of addition assays with isolated ellagic acid. Vero cells were treated with compound
571 prior to infection (pre-treatment), during the infection period (during infection) or after infection
572 (post-treatment) with MR766 (panel C) and HPF 2013 (panel D). Data are reported as percentage of
573 infection in comparison to untreated control. Error bars represent the standard error of the means for
574 three independent experiments. Ellagic acid was resuspended in a DMSO solution.

575

576 **Table 1.** Anti-ZIKV-MR766 activity of the pomegranate leaf ethanolic extract (PGL8)

Virus	Sample	EC ₅₀ ^a (µg/mL) (95% CI) ^b	EC ₉₀ ^c (µg/mL) (95% CI)	CC ₅₀ ^d (µg/mL) (95% CI)	CC ₉₀ ^e (µg/mL) (95% CI)	SI ^f
MR766	PGL8	11.40 (7.84-16.57)	75.32 (25.7-113.3)	123.6 (104.0-146.7)	443 (313.3-559.2)	10.84
HSV-2	PGL8	3.29 (1.64-6.56)	120.2 (18.5-224.1)	154.9 (112.3-213.7)	1633 (860-2023.3)	47.08
Vaccinia virus	PGL8	n.a. ^g	n.a.	-	-	n.a.
	Fractions	EC ₅₀ (µg/mL) (95% CI)	EC ₉₀ (µg/mL) (95% CI)	CC ₅₀ (µg/mL) (95% CI)	CC ₉₀ (µg/mL) (95% CI)	SI
MR766	PGSum85	16.20 (12.4-21.2)	95.27 (45.5-129.5)	76.1 (48.4-120)	143 (74.5-184.4)	4.69
	PGAut85	10.4 (7.08-15.2)	43.96 (17.3-111.7)	73.4 (51.6-104)	156 (88.3-216.2)	7.05
	PGSum95	n.a.	n.a.	14.2 (12.3-16.4)	32.2 (22.3-46.6)	-
	PGAut95	n.a.	n.a.	17.5 (11.9-25.8)	37.2 (18-76.6)	-

577 ^aEC₅₀: half maximal effective concentration; ^bCI: confidence interval; ^cEC₉₀: 90% effective concentration; ^dCC₅₀: half
578 maximal cytotoxic concentration; ^eCC₉₀: 90% cytotoxic concentration; ^fSI: selectivity index; ^gn.a.: not assessable.

579

580

581

582

583 **Table 2.** List of identified and putatively identified compounds in leaf extract. Each compound is
 584 referred through its relative retention time, UV maxima λ absorption, molecular formula,
 585 pseudomolecular ions (ESI^+ and ESI^-), ion fragments generated by Product Ion Scan mode (PIS) and
 586 identified or tentatively identified compound names. The identification confidence value and the
 587 literature reference that indicates the presence of the compounds in pomegranate are also reported.

N°	RT	λ_{max} (nm)	Molecular formula	$[M+H]^+$	$[M-H]^-$	Supp. MW	MS^{2+} m/z	MS^{2-} m/z	Compound name	Identif. conf. ^b	Ref.
1 ^a	1.649	272	C ₇ H ₆ O ₅	/	169	170		125 110	Gallic acid	1	[30]
2	7.373	314	C ₁₅ H ₁₈ O ₈	/	325	326		163 145	Coumaric acid hexoside	2	[31]
3	11.657	273 357	C ₁₃ H ₈ O ₈	/	291	292		247	Brevifolin – carboxyl acid	2	[31]
4	14.364	268		801 151	799	800	151	301	Ellagic derivative	2	[30]
5	19.032	270 350		611	935 655 609	610	151	301 137	Ellagitannin	3	
6	19.420	251 360	C ₂₀ H ₁₆ O ₁₃	465	463	464	/	301	Ellagic acid glucoside	2	[30]
7	24.091	274 365	C ₄₁ H ₂₈ O ₂₇	953	951	952	/	933 301	Galloyl- HHDP- DHHDP- hexoside (Granatin B)	2	[30]
8 ^a	24.366	253 347	C ₂₁ H ₂₀ O ₁₁	449	447	448	287	285	Luteolin 7- O-glucoside	1	[31]
9 ^a	25.994	252 366	C ₁₄ H ₆ O ₈		301	302	/	284 229 185	Ellagic acid	1	[30]
9 ^a a	25.994		C ₂₇ H ₃₀ O ₁₆	611	609	610			Rutin	1	[30]
10 a	27.426	255 353	C ₂₁ H ₂₀ O ₁₂	465	463	464	303 229 153	301 255 151	Quercetin 3-O- glucoside	1	[30]
11 a	28.885	266 336	C ₂₁ H ₂₀ O ₁₀	433	431	432	271	269	Apigenin 7-O- glucoside	1	[31]

12	30.971	268 332		433	431	432	271	269 195 151 117	Apigenin glycoside	3	
13 a	31.719	267 337	C ₂₁ H ₂₀ O ₁₁	449	447	448	287	285 257	Luteolin 4'-O- glucoside	1	[30]
14	33.223	268 340		449	447	448	287 153	285 151	Luteolin glycoside 1	3	
15	37.253	268 340		419	417	418	287 153	285 257 175 151	Luteolin glycoside 2	3	
16 a	42.958	252 347	C ₁₅ H ₁₀ O ₆	287	285	286	153 135 117	171 151 133 115	Luteolin	1	[30]
17 a	45.538	267 336	C ₁₅ H ₁₀ O ₅	271	269	270	163 153 119	151 117	Apigenin	1	[31]
*	50.201	-	C ₃₀ H ₄₈ O ₃	457	455	456	333 239 191 189	407	Oleanolic acid	1	[31]
*	50.201	-	C ₃₀ H ₄₈ O ₃	457	455	456	333 239 191 189	407	Betulinic acid	1	[31]
*	50.201	-	C ₃₀ H ₄₈ O ₃	457	455	456	333 239 191 189	407	Ursolic acid	1	[31]

588 a Compounds identified by comparing with reference standards.

589 b An Identification Confidence according to the request of the Chemical Analysis Working Group (CAWG, 2007) [32] is indicated: Level 1: Identified
590 compound (A minimum of two independent orthogonal data (such as retention time and mass spectrum) compared directly to an authentic reference
591 standard; Level 2: Putatively annotated compound (Compound identified by analysis of spectral data and similarity to bibliographic data); Level 3:
592 Putatively characterised class compound; Level 4: unknown compound.

593

594 **Table 3.** Anti-ZIKV-MR766 activity of phenolic and triterpenic compounds. For each concentration
 595 tested, the percentage of infection in comparison to control is reported as mean value \pm SD. The
 596 molarities of the compounds is reported in square brackets, referred to 3.7 $\mu\text{g/mL}$, 11 $\mu\text{g/mL}$ and 33
 597 $\mu\text{g/mL}$ concentrations, respectively.

598

Compounds	3.7 $\mu\text{g/mL}$	11 $\mu\text{g/mL}$	33 $\mu\text{g/mL}$
Apigenin	99.0 \pm 7.1 [13.7 μM]	n.a. ^a [40.7 μM]	n.a. [122.1 μM]
Apigenin 7-O-glucoside	103.6 \pm 8.9 [8.5 μM]	101.2 \pm 3.7 [25.4 μM]	102.5 \pm 2.8 [76.2 μM]
Betulinic acid	99.3 \pm 1.1 [8.1 μM]	101.5 \pm 6.4 [24.1 μM]	95.5 \pm 10.7 [72.3 μM]
Luteolin	102.9 \pm 4.1 [13 μM]	n.a. [38.5 μM]	n.a. [115.5 μM]
Luteolin 4-O-glucoside	103.0 \pm 1.4 [8.3 μM]	96.0 \pm 5.7 [24.5 μM]	102.8 \pm 8.8 [73.6 μM]
Luteolin 7-O-glucoside	105.0 \pm 5.7 [8.3 μM]	102.0 \pm 11.3 [24.5 μM]	100.0 \pm 3.3 [73.6 μM]
Oleanolic acid	99.5 \pm 9.2 [8.1 μM]	103.8 \pm 3.2 [24.1 μM]	104.3 \pm 6.7 [72.3 μM]
Quercetin 3-O-glucoside	105.5 \pm 6.4 [8.0 μM]	103.1 \pm 9.8 [23.8 μM]	106.5 \pm 4.6 [71.3 μM]
Rutin	103.3 \pm 9.5 [6.1 μM]	95.4 \pm 20.6 [18.0 μM]	107 \pm 2.4 [54.1 μM]
Ursolic acid	100.0 \pm 11.9 [8.1 μM]	79.7 \pm 2.3 [24.1 μM]	n.a. [72.3 μM]
Ellagic acid	83.8 \pm 11.5 [12.2 μM]	43.3 \pm 1.3 [36.4 μM]	0.0 \pm 0.8 [109.2 μM]

599 ^an.a., not assessable

600 Betulinic acid, oleanolic acid, ursolic acid, apigenin were resuspended in a DMSO/H₂O solution (70%/30%); apigenin 7-
 601 O-glucoside, luteolin, luteolin 4-O-glucoside, luteolin 7-O-glucoside, quercetin 3-O-glucoside, rutin and ellagic acid were
 602 were resuspended in a DMSO solution.

603

604 **Table 4.** Anti-ZIKV activity of ellagic acid

	Virus	EC ₅₀ ^a (μM) (95% CI ^b)	EC ₉₀ ^c (μM) (95% CI ^b)	CC ₅₀ ^d (μM)	SI ^e
Commercial ellagic acid	MR766	36.22 (28.91-45.37)	93.05 (53.17-162.8)	496.5	13.7
	HPF2013	20.99 (16.48-26.74)	53.23 (31.11-91.09)	496.5	23.7
Isolated ellagic acid	MR766	30.86 (26.02-36.6)	42.64 (33.98-53.51)	446.85	14.5
	HPF2013	46.23 (37.88-56.41)	141.2 (85.90-232.0)	446.85	9.7

605 ^aEC₅₀: half maximal effective concentration; ^bCI: confidence interval; ^cEC₉₀: 90% effective concentration; ^dCC₅₀: half
 606 maximal cytotoxic concentration; ^eSI: selectivity index. Ellagic acid was resuspended in a DMSO solution.

607

608

609

610

611

612

613

614

615

616

617

618

619


620

621

622


623

624




625

626



627

628



629

630